Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Obsessive Compulsive Disorder
NCT03300947Phase 1Completed
- Sponsor
- University of Arizona
- Start
- Jan 2019
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in obsessive compulsive disorder (OCD) (3 arms), sponsored by University of Arizona. Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 9 weeks. Started Jan 2019; status: completed.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT03300947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300947.